Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27859545 | 0.92 | LMNA (0.41) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL14322076 | 0.90 | LMNA (0.50) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL1705701 | 0.89 | HPGD (0.51) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL9384 | 0.85 | LMNA (0.45) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL27936474 | 0.83 | LMNA (0.50) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL12897250 | 0.83 | LMNA (0.50) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL985927 | 0.82 | ALDH1A1 (0.59) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL2482829 | 0.82 | ALDH1A1 (0.59) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL16060069 | 0.82 | ALDH1A1 (0.59) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL12897268 | 0.80 | KMT2A (0.47) | LMNAPOLBUSP2SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567445-A | It can be used as 2 phenyl 3H imidazos [4,5 B] pyridine derivates of mammal EGFR-TK ROR1 activities inhibitor | 坎塞拉有限公司 | 2018-01-09 | — | — | CN | claimed |
| EP-2001875-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1841755-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2007-10-10 | — | — | EP | claimed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| WO-2006070001-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2006-07-06 | — | — | WO | claimed |
| EP-1080091-A1 | NOVEL 1,3,8-TRIAZASPIRO[4.5]DECANONES WITH HIGH AFFINITY FOR OPIOID RECEPTOR SUBTYPES | Novo Nordisk A/S (DK) | 2001-03-07 | — | — | EP | claimed |
| WO-1999059997-A1 | NOVEL 1,3,8-TRIAZASPIRO[4.5]DECANONES WITH HIGH AFFINITY FOR OPIOID RECEPTOR SUBTYPES | NOVO NORDISK A/S (DK) | 1999-11-25 | — | — | WO | claimed |
| EP-4554572-A2 | MIXTURES AND USES OF (2E)-3-(1,3-BENZODIOXOL-5-YL)-N-PHENYL-N-(TETRAHYDRO-3-FURANYL)-2-PROPENAMIDE | Symrise AG (DE) | 2025-05-21 | — | — | EP | disclosed |
| US-20240101538-A1 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2024-03-28 | — | — | US | disclosed |
| CN-116874448-A | Hydrazine and air mediated non-activated C (sp 3 ) Method for adding-H bond to electron-deficient olefin | 昆明理工大学 | 2023-10-13 | — | — | CN | disclosed |
| EP-3675809-B1 | USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS | BASF SE (DE) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022207944-A9 | NOVEL MIXTURES AND USES OF (2E)-3-(1,3-BENZODIOXOL-5-YL)-N-PHENYL-N-(TETRAHYDRO-3-FURANYL)-2-PROPENAMIDE | SYMRISE AG (DE) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022207944-A2 | NOVEL MIXTURES AND USES OF (2E)-3-(1,3-BENZODIOXOL-5-YL)-N-PHENYL-N-(TETRAHYDRO-3-FURANYL)-2-PROPENAMIDE | SYMRISE AG (DE) | 2022-10-06 | — | — | WO | disclosed |
| WO-2006070001-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2006-07-06 | — | — | WO | disclosed |
| US-20050107444-A1 | Amide compounds and methods of using the same | GLAXOSMITHKLINE LLC | 2005-05-19 | — | — | US | disclosed |
| US-6867200-B1 | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-6410792-B1 | OBESITY DISEASES | BAYER CORPORATION | 2002-06-25 | — | — | US | disclosed |
| EP-0424525-B1 | NOVEL AMINES AND THEIR USE | MITSUI PETROCHEMICAL IND (JP) | 1994-12-21 | — | — | EP | disclosed |
| US-5192799-A | Coumaran group containing amine compounds and their acid addition salts and quaternary ammonium salts and the use thereof as anti arrhythmic agents and as psychotropic agents | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-09 | — | — | US | disclosed |
| EP-0424525-A1 | NOVEL AMINES AND THEIR USE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101538-A1 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | AURKC, AURKA, AURKB | LMNA 1321/4885POLB 2156/4885USP2 3101/4885 |
| US-20050107444-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | LMNA 2650/4885POLB 3888/4885USP2 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.